sphingomyelin synthase

SMS2-IN-2 (SMS2 inhibitors) is a potent, selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor, (IC50s of 100 and 56 μM for SMS2 and SMS1, respectively). SMS2-IN-2 has anti-chronic inflammatory activity.

D609 (Tricyclodecan-9-yl-Xanthogenate) has a wide range of biological activities including antioxidant, antiapoptotic, anticholinergic, antitumor, anti-inflammatory, antiviral, antiproliferative, and neuroprotective activities.D609 acts by inducing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS). D609 acts by causing competitive inhibition of PC-specific phospholipase C (PC-PLC) and sphingomyelin synthase (SMS).

Ly93 is a selective and orally active sphingomyelin synthase 2 (SMS2) inhibitor (IC50: 91 nM) used for studying atherosclerosis.

Malabaricone C is a bioactive chemical.

Ceramide phosphoethanolamine (CPE) is an analog of sphingomyelin that contains ethanolamine rather than choline as the head group. It is the principal membrane phospholipid in invertebrates such as Drosophila, which lacks sphingomyelin. It is only produced in small amounts in mammalian cells, accounting for approximately 0.02 mol% of total phospholipids in mouse testis and brain. In Drosophila, CPE is biosynthesized by CPE synthase from ceramide and cytidine diphosphate-ethanolamine in the Golgi lumen. In mammals, it is biosynthesized by sphingomyelin synthase 2 (SMS2) in the plasma membrane and by sphingomyelin synthase-related protein (SMSr) in the endoplasmic reticulum (ER). In Drosophila, CPE has a role in glial ensheathment of axons. Disrupting CPE synthesis by depleting SMSr in vitro in mammalian cells leads to an accumulation of ER ceramides, which are then mislocalized to the mitochondria, inducing apoptosis. However, ceramide levels are not altered in transgenic mice lacking SMSr catalytic activity. CPEs (bovine) is a mixture of CPEs with variable N-acyl chain lengths.

SMS1-IN-1 is a potent inhibitor of sphingomyelin synthase 1 (SMS1, IC50 = 2.1 μM), and can be used in the atherosclerosis studies.

WYFA-15 is an inhibitor of sphingomyelin synthase 1 (SMS1) that has been shown to protect mice from lethal SFTSV infection and reduce the replication and pathogenicity of SARS-CoV-2. WYFA-15 is applicable for antiviral research.